Cure SCD倡议:镰状细胞病基因治疗试验通用数据元素推荐
美国国家心肺血液研究所发起的Cure Sickle Cell Initiative(CureSCi)通过五个工作组历时1.5年制定镰状细胞病(SCD)基因治疗临床试验的通用数据元素(CDE)标准,并经过60天公众评议。该标准包含42项工具推荐和49份病例报告表模板,公开于CureSCi和NIH网站,旨在促进多中心研究启动、跨研究结局比较及数据质量提升。
要点
- 基因治疗试验应采用CureSCi推荐的CDE以促进数据互操作与跨研究比较
- CDE包含42项工具推荐和49份不同研究阶段的病例报告表模板
- 标准公开可获取,有助于多中心研究启动和研究人员培训
核心结论
- CureSCi制定的SCD基因治疗CDE推荐基于现有共识数据元素,可促进多中心临床研究启动并提高跨研究结局可比性。
研究设计与样本
- 由美国国家心肺血液研究所创建的CureSCi发起,五个工作组(含SCD患者、利益相关者、临床医生和研究人员)历时1.5年制定,并纳入60天公众评议反馈。
主要发现
- 工作组审查了美国血液学会、美国食品药品监督管理局、PhenX共识措施目录等来源的当前定义,制定了推荐用于任何基因治疗临床试验的全面数据点和变量列表。
- 除数据元素外,还提供了42项工具推荐(包括患者报告结局测量信息系统和NIH Toolbox)以及49份用于研究不同阶段(如人口学、疾病史、治疗和结局)的病例报告表模板。
关键数值与推荐
- SCD CDE公开可获取于CureSCi网站(curesickle.org/datatools-overview)和NIH Repository网站(cde.nlm.nih.gov/home)。
- 包含42项工具推荐和49份病例报告表模板。
临床怎么用
- 在SCD基因治疗临床试验中采用CureSCi CDE标准,以促进多中心研究启动、跨研究结局比较和数据质量提升。
- 利用公开的CDE和模板病例报告表加速临床研究准备并教育新的临床研究者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Cure Sickle Cell Initiative (CureSCi), created by the National Heart, Lung, and Blood Institute, has developed data standards to increase interoperability and meta-analysis of studies specifically investigating gene therapy for sickle cell disease (SCD). The aims of the CureSCi Common Data Elements (CDE) initiative are to facilitate the development of safe, effective, and accessible gene therapies. Five working groups (WGs) comprising people living with SCD, stakeholders, clinicians, and researchers reviewed current definitions used for SCD clinical studies, including those from the American Society of Hematology, US Food and Drug Administration, PhenX catalog of consensus measures for phenotypes and exposures, and others. The WGs met over 1.5 years to develop a comprehensive list of defined data points and variables recommended for any gene therapy clinical trial that incorporated feedback from a 60-day public review period. The SCD CDEs are publicly available on the CureSCi (curesickle.org/datatools-overview) and the National Institutes of Health (NIH) Repository (cde.nlm.nih.gov/home) websites. In addition to data elements, there are 42 instrument recommendations, including those from the Patient-Reported Outcomes Measurement Information System and NIH Toolbox, and 49 template case report forms for various stages of a study (eg, demographic, disease history, treatment, and outcome). CureSCi data element recommendations build upon current consensus data elements and facilitate the start-up of multicenter clinical research efforts. This standardized set of clinical research recommendations will increase the ability to compare outcomes across studies, increase data quality, and help educate new clinical investigators in the field of SCD gene therapy research.
引用
- Lanzkron S, Coleman-Cowger VH, Thompson AA, et al. Cure Sickle Cell Initiative recommendations on common data elements for sickle cell disease gene therapy trials. Blood Adv. 2026. PMID: 41941692. doi:10.1182/bloodadvances.2025019400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。